Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

Joya Chandra, Jeannette Tracy, David Loegering, Karen Flatten, Srdan Verstovsek, Miloslav Beran, Mercedes Gorre, Zeev Estrov, Nicholas Donato, Moshe Talpaz, Charles Sawyers, Kapil Bhalla, Judith Karp, Edward Sausville, Scott H. Kaufmann

Research output: Contribution to journalArticle

Abstract

The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to secondgeneration kinase inhibitors such as BMS-354825 or AMN107. Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates. Recent findings have in addition implicated reactive oxygen species (ROS) in the cytotoxic mechanism of adaphostin. In view of this unique mode of action, we examined the effects of adaphostin on numerous imatinib-resistant leukemia models, including imatinib-resistant CML and Ph+ ALL cell lines, cells harboring point mutations in BCR/ABL, and specimens from imatinib-resistant CML patients, using assays for intracellular ROS, apoptosis, and clonogenicity. Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death. Collectively, these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL.

Original languageEnglish (US)
Pages (from-to)2501-2506
Number of pages6
JournalBlood
Volume107
Issue number6
DOIs
StatePublished - Mar 15 2006
Externally publishedYes

Fingerprint

NSC 680410
Oxidative stress
Oxidative Stress
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reactive Oxygen Species
Phosphotransferases
Tyrphostins
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Imatinib Mesylate
Cell death
Point Mutation

ASJC Scopus subject areas

  • Hematology

Cite this

Chandra, J., Tracy, J., Loegering, D., Flatten, K., Verstovsek, S., Beran, M., ... Kaufmann, S. H. (2006). Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood, 107(6), 2501-2506. https://doi.org/10.1182/blood-2005-07-2966

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. / Chandra, Joya; Tracy, Jeannette; Loegering, David; Flatten, Karen; Verstovsek, Srdan; Beran, Miloslav; Gorre, Mercedes; Estrov, Zeev; Donato, Nicholas; Talpaz, Moshe; Sawyers, Charles; Bhalla, Kapil; Karp, Judith; Sausville, Edward; Kaufmann, Scott H.

In: Blood, Vol. 107, No. 6, 15.03.2006, p. 2501-2506.

Research output: Contribution to journalArticle

Chandra, J, Tracy, J, Loegering, D, Flatten, K, Verstovsek, S, Beran, M, Gorre, M, Estrov, Z, Donato, N, Talpaz, M, Sawyers, C, Bhalla, K, Karp, J, Sausville, E & Kaufmann, SH 2006, 'Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance', Blood, vol. 107, no. 6, pp. 2501-2506. https://doi.org/10.1182/blood-2005-07-2966
Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M et al. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006 Mar 15;107(6):2501-2506. https://doi.org/10.1182/blood-2005-07-2966
Chandra, Joya ; Tracy, Jeannette ; Loegering, David ; Flatten, Karen ; Verstovsek, Srdan ; Beran, Miloslav ; Gorre, Mercedes ; Estrov, Zeev ; Donato, Nicholas ; Talpaz, Moshe ; Sawyers, Charles ; Bhalla, Kapil ; Karp, Judith ; Sausville, Edward ; Kaufmann, Scott H. / Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. In: Blood. 2006 ; Vol. 107, No. 6. pp. 2501-2506.
@article{be0c7dd170a7482c920c2a27bb7f7894,
title = "Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance",
abstract = "The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to secondgeneration kinase inhibitors such as BMS-354825 or AMN107. Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates. Recent findings have in addition implicated reactive oxygen species (ROS) in the cytotoxic mechanism of adaphostin. In view of this unique mode of action, we examined the effects of adaphostin on numerous imatinib-resistant leukemia models, including imatinib-resistant CML and Ph+ ALL cell lines, cells harboring point mutations in BCR/ABL, and specimens from imatinib-resistant CML patients, using assays for intracellular ROS, apoptosis, and clonogenicity. Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death. Collectively, these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL.",
author = "Joya Chandra and Jeannette Tracy and David Loegering and Karen Flatten and Srdan Verstovsek and Miloslav Beran and Mercedes Gorre and Zeev Estrov and Nicholas Donato and Moshe Talpaz and Charles Sawyers and Kapil Bhalla and Judith Karp and Edward Sausville and Kaufmann, {Scott H.}",
year = "2006",
month = "3",
day = "15",
doi = "10.1182/blood-2005-07-2966",
language = "English (US)",
volume = "107",
pages = "2501--2506",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

AU - Chandra, Joya

AU - Tracy, Jeannette

AU - Loegering, David

AU - Flatten, Karen

AU - Verstovsek, Srdan

AU - Beran, Miloslav

AU - Gorre, Mercedes

AU - Estrov, Zeev

AU - Donato, Nicholas

AU - Talpaz, Moshe

AU - Sawyers, Charles

AU - Bhalla, Kapil

AU - Karp, Judith

AU - Sausville, Edward

AU - Kaufmann, Scott H.

PY - 2006/3/15

Y1 - 2006/3/15

N2 - The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to secondgeneration kinase inhibitors such as BMS-354825 or AMN107. Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates. Recent findings have in addition implicated reactive oxygen species (ROS) in the cytotoxic mechanism of adaphostin. In view of this unique mode of action, we examined the effects of adaphostin on numerous imatinib-resistant leukemia models, including imatinib-resistant CML and Ph+ ALL cell lines, cells harboring point mutations in BCR/ABL, and specimens from imatinib-resistant CML patients, using assays for intracellular ROS, apoptosis, and clonogenicity. Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death. Collectively, these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL.

AB - The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to secondgeneration kinase inhibitors such as BMS-354825 or AMN107. Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates. Recent findings have in addition implicated reactive oxygen species (ROS) in the cytotoxic mechanism of adaphostin. In view of this unique mode of action, we examined the effects of adaphostin on numerous imatinib-resistant leukemia models, including imatinib-resistant CML and Ph+ ALL cell lines, cells harboring point mutations in BCR/ABL, and specimens from imatinib-resistant CML patients, using assays for intracellular ROS, apoptosis, and clonogenicity. Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death. Collectively, these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL.

UR - http://www.scopus.com/inward/record.url?scp=33644755497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644755497&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-07-2966

DO - 10.1182/blood-2005-07-2966

M3 - Article

C2 - 16291594

AN - SCOPUS:33644755497

VL - 107

SP - 2501

EP - 2506

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -